跳至主要内容
临床试验/NCT00664209
NCT00664209终止3 期

Helicobacter Pylori Eradication and Motor Fluctuations in Parkinson's Disease

University of California, Los Angeles1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
入组人数
64
试验地点
1
主要终点
"Off" Time

研究概览

简要总结

The purpose of this study is to determine whether treatment of H. pylori (an infection of the stomach) improves treatment effectiveness in patients with Parkinson's disease and motor fluctuations.

详细描述

Previous investigations have demonstrated that treatment of Helicobacter pylori with antibiotics leads to improved absorption and pharmacokinetics of levodopa. This may potentially benefit patients with Parkinson's disease who have motor fluctuations, specifically excessive "off" time, when their levodopa is not working to control symptoms. We seek to identify the frequency of H. pylori infection in this population using standard lab assays and determine whether eradication with standard triple therapy results in improved clinical response to medication.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Active-placebo

Other

These subject receive treatment with active triple therapy followed by treatment with placebo therapy.

干预措施: clartihromycin, amoxicillin, and omeprazole (Drug)

Active-placebo

Other

These subject receive treatment with active triple therapy followed by treatment with placebo therapy.

干预措施: placebo (Drug)

Placebo-active

Other

These subject receive treatment with placebo therapy followed by treatment with active triple therapy.

干预措施: clartihromycin, amoxicillin, and omeprazole (Drug)

Placebo-active

Other

These subject receive treatment with placebo therapy followed by treatment with active triple therapy.

干预措施: placebo (Drug)

结局指标

主要结局

"Off" Time

时间窗: 2 months

Average total daily "off" time (measured by patient symptom diaries) in hours

次要结局

  • Improvement in UDPRS Part III(2 months)
  • Improvement in UPDRS Total Scores(2 months)
  • Improvement in Quality of Life as Assessed by PDQ-39(2 months)
  • Participants With Side Effects From Study Treatment(2 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jeff Bronstein

Professor of Neurology

University of California, Los Angeles

研究点 (1)

Loading locations...

相似试验

Treating H. Pylori in Parkinson's Patients With... | 临床试验